Dear Editor,

I recently read the article *Threshold for Positivity and Optimal Dipyrone Concentration in Flow Cytometry-Assisted Basophil Activation Test* by Hagau et al., in the August 2013 issue of AAIR, where the authors assessed the usefulness of basophil activation tests (BATs) in the diagnosis of allergy to dipyrone.[@B1] Allergy to dipyrone still represents a main concern and pyrazolones are considered a major cause of immediate IgE-mediated reactions to drugs in many countries.[@B2] A case of drug rash with eosinophilia and systemic symptomatology (DRESS) attributed to dipyrone was recently reported; however, the authors could not rule out a possible interfering role attributed to herbal mixtures and other drugs.[@B3] BATs represent an interesting tool to diagnose drug hypersensitivity, though with some criticism about their performance and interpretation.[@B4] Basophils captured in flow cytometry by CD193 (CCR3)-phycoerythrin (PE) may be contaminated by CD3^+^ expressing cells, leading to possible bias.[@B5] Despite this issue, Hagau and colleagues reported that commercial BAT equipped with a Flow2-CAST technique, showed a sensitivity as low as 0.25 µg/mL dipyrone, about 3 orders of magnitude lower than previous reported evidence.[@B1],[@B2] In the paper by Gomez et al., a commercial BAT using an anti-IgE/CD63 protocol (instead of a CCR3/CD63) reported that the lowest dose able to trigger CD63 upregulation over the 5% threshold, was 0.25 mg/mL dipyrone (matamizole); Hagau and co-workers used the same CD63% threshold.[@B1] It apppears quite difficult to attribute this sensitivity improvement to superior BAT performance (at least in regards to the phenotyping protocol).[@B5] CCR3 has been recently reviewed as a phenotyping marker and compared to other flow cytometry approaches.[@B5] The eotaxin receptor is commonly expressed on eosinophils,[@B6] together with CD63 (which is only present on activated cells)[@B7]; however, in a SSC (side scatter)/CCR3 scatter plot, eosinophils and basophils can be clearly separated and eosinophils should not affect a Flow2-CAST BAT performance. Yet CCR3 is downregulated during basophil activation[@B5] and the proportion of gated basophils evaluated as up-regulating CD63 is higher than the same calculated on resting, non activated basophils, if gate is set at a fixed threshold (usually ≤5%). In a SSC/CCR3 gating plot basophils may be underestimated, due to CCR3 downregulation and contamination by SSC^low\ scattered^/CD3^+^ lymphocytes. If we consider that CCR3-PE^bright^ basophils express homogeneously very low amount of membrane CD63 (for example 5%), a supposed reduction of 52% of 500 gated CCR3-PE^bright^ cells (due to activation), might shift the threshold to 1.53%. This would mean that a proportion of CD63^neg^ cells enter the right side of the threshold and lead to a higher CD63% evaluation. The bias may be significant when CD63% is close to the threshold. In the paper, 1 SI is calculated on the number of basophils and Table 1[@B1] reports 6/20 samples (30%) with 5.3\< SI \<9.1. The simultaneous evaluation of CD63-FITC~MFI~ and CD63% should prevent a bias4; however, other bias can still occur. The operator might capture more CCR3-PE^bright^ cells than the negative control: in this case, as CCR3-PE^bright^ basophils are negative, the MFI ratio CD63^pos^/CD63^neg^ may decrease while CD63% increase. In the lack of a CD3 marker, the operator may capture low SSC cells that express CCR3 but not CD63: this occurrence may also decrease the MFI ratio CD63^neg^/CD63^pos^ and increase CD63%. Lowest doses of dipyrone may show a low expression of CD63-FITC (as median MFI) but relatively higher CD63% expressing basophils. This may prompt researchers to evaluate BAT as a valuable tool to probe very low doses of dipyrone in allergy; however, the absence of a flow cytometry plot reported by the authors1 makes it difficult to address this point and to elucidate possible causes about the high sensitivity reported.
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